Stock Scorecard



Stock Summary for TG Therapeutics Inc (TGTX) - $39.86 as of 3/28/2025 9:09:29 PM EST

Total Score

11 out of 30

Safety Score

50 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TGTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TGTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TGTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TGTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TGTX (50 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 1
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for TGTX

TG Therapeutics ( TGTX ) technical analysis - TG Therapeutics ( NASDAQ:TGTX ) 3/21/2025 3:50:00 PM
Strength Seen in TG Therapeutics ( TGTX ) : Can Its 10.2% Jump Turn into More Strength? 3/17/2025 9:33:00 AM
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance 3/11/2025 8:05:00 PM
Why TG Therapeutics Stock Was Soaring This Week 3/7/2025 10:23:00 PM
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting 3/7/2025 12:30:00 PM
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - TG Therapeutics ( NASDAQ:TGTX ) 3/7/2025 12:30:00 PM
Company News for Mar 4, 2025 3/4/2025 8:20:00 AM
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update 2/26/2025 12:30:00 PM
Novavax to Report Q4 Earnings: Here's What You Can Expect 2/19/2025 2:36:00 PM
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ( ublituximab ) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - TG Therapeutics ( NASDAQ:TGTX ) 2/18/2025 12:30:00 PM

Financial Details for TGTX

Company Overview

Ticker TGTX
Company Name TG Therapeutics Inc
Country USA
Description TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/29/2025

Stock Price History

Last Day Price 39.86
Price 4 Years Ago 19.00
Last Day Price Updated 3/28/2025 9:09:29 PM EST
Last Day Volume 1,642,856
Average Daily Volume 2,974,532
52-Week High 43.32
52-Week Low 12.93
Last Price to 52 Week Low 208.28%

Valuation Measures

Trailing PE 268.00
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 52.35
Free Cash Flow Ratio 20.13
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 6.25
Total Cash Per Share 1.98
Book Value Per Share Most Recent Quarter 1.54
Price to Book Ratio 28.40
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 19.47
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 157,071,000
Market Capitalization 6,260,850,060
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.72%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -97.30%
Annual Earnings Growth 84.52%
Reported EPS 12 Trailing Months 0.15
Reported EPS Past Year 0.14
Reported EPS Prior Year 0.01
Net Income Twelve Trailing Months 23,383,000
Net Income Past Year 23,383,000
Net Income Prior Year 12,672,000
Quarterly Revenue Growth YOY 146.00%
5-Year Revenue Growth 363.28%
Operating Margin Twelve Trailing Months 27.70%

Balance Sheet

Total Cash Most Recent Quarter 311,000,000
Total Cash Past Year 311,000,000
Total Cash Prior Year 217,500,000
Net Cash Position Most Recent Quarter 66,571,000
Net Cash Position Past Year 66,571,000
Long Term Debt Past Year 244,429,000
Long Term Debt Prior Year 100,403,000
Total Debt Most Recent Quarter 244,429,000
Equity to Debt Ratio Past Year 0.48
Equity to Debt Ratio Most Recent Quarter 0.48
Total Stockholder Equity Past Year 222,364,000
Total Stockholder Equity Prior Year 160,502,000
Total Stockholder Equity Most Recent Quarter 222,364,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -40,562,000
Free Cash Flow Per Share Twelve Trailing Months -0.26
Free Cash Flow Past Year -40,562,000
Free Cash Flow Prior Year -31,413,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.47
MACD Signal 2.45
20-Day Bollinger Lower Band 25.46
20-Day Bollinger Middle Band 33.42
20-Day Bollinger Upper Band 41.39
Beta 2.30
RSI 58.37
50-Day SMA 25.00
150-Day SMA 17.04
200-Day SMA 18.47

System

Modified 3/28/2025 9:04:56 AM EST